Wiechert A, Reinhard G, Tüting T, Uerlich M, Bieber T, Wenzel J
Dermatologische Klinik, Universitätsklinikum Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn.
Hautarzt. 2009 Aug;60(8):651-2, 654. doi: 10.1007/s00105-008-1673-1.
A 62-year-old patient treated for 9 years with hydroxyurea for chronic myeloproliferative disease developed multiple cutaneous neoplasms. Hydroxyurea minimizes DNA synthesis via inhibition of the enzyme ribonucleotide reductase and is used to treat hematological malignancies. The most important and severe side-effect is a dose-dependent myelodepression. An association with multiple skin tumors has been reported. The presented case emphasizes this potential risk of hydroxyurea therapy. Continuous dermatologic monitoring of patients treated with hydroxyurea is recommended.
一名62岁的慢性骨髓增殖性疾病患者接受羟基脲治疗9年,出现了多发性皮肤肿瘤。羟基脲通过抑制核糖核苷酸还原酶来减少DNA合成,用于治疗血液系统恶性肿瘤。最重要且严重的副作用是剂量依赖性骨髓抑制。已有报道称其与多发性皮肤肿瘤有关联。本病例强调了羟基脲治疗的这一潜在风险。建议对接受羟基脲治疗的患者进行持续的皮肤科监测。